Physician profile
Erin Smith
NPI 1740957646
$2,805.13
in general payments reported to CMS, 2019-2025
30 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $298 · 2023: $257 · 2024: $714 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $523.70 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $341.98 | 2022-2025 | Airsupra, Farxiga, Lokelma |
| Abbvie INC. | $294.88 | 2025 | |
| Novo Nordisk INC | $224.29 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $156.26 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $147.06 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $144.33 | 2025 | Spravato |
| Pfizer INC. | $103.46 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.16 | 2024-2025 | |
| Amgen INC. | $73.09 | 2021-2025 | Repatha, Repatha |
| Axsome Therapeutics, INC. | $70.77 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $70.21 | 2024-2025 | Voquezna |
| Corium, LLC | $61.42 | 2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.28 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $44.88 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.16 | 2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $40.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $39.76 | 2024-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $37.89 | 2023-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $34.76 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $34.12 | 2024-2025 | Nexletol |
| Philips North America LLC | $27.85 | 2022 | |
| Lilly USA, LLC | $27.60 | 2024 | Jardiance, Mounjaro |
| Radius Health, INC. | $24.33 | 2024 | Tymlos |
| Shield Therapeutics INC | $24.07 | 2025 | |
| Beta Bionics, INC. | $23.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Aimmune Therapeutics, INC. | $19.48 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2025 | |
| Astellas Pharma US INC | $13.63 | 2023 | Cresemba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.